Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P2BNCTBforrMG
jRCTs051180218Phase 2Completed
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in glioma. Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on jRCTs051180218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180218.